Quebec Makes the Move to Reimburse Large B-Cell Lymphoma Treatment

MONTREAL, Aug. 17, 2023 /CNW/ – Incyte Biosciences Canada is pleased to announce that Quebec has made Minjuvi® (tafasitamab) in combination with lenalidomide accessible with reimbursement under the Régie de l’assurance maladie du Québec (RAMQ) for eligible patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This first listing follows a positive clinical recommendation by the health technology assessment agency Institut national d’excellence en santé et

Breast Cancer Screening Public Document Submissions

The Canadian Task Force on Preventive Health Care (CTFPHC)  is currently undertaking an update of the Canadian Breast Cancer Screening Guidelines. The CTFPHC has asked for submissions of potentially relevant evidence on Breast Cancer Screening from the public and academia. The types of documents they are accepting include: peer-reviewed journal articles, government reports, reports from health organizations and other relevant documents. The CSBI will be compiling documentation to

Check Out Our Submission for the 2024 Federal Budget

We have made a number of suggestions to the federal government to improve cancer care across the country. We have made the recommendations as part of the government’s pre-budget consultations. The federal government put out a call in June for Canadians to convey their priorities for the upcoming budget next year. Among our recommendations is for the government to allocate funding for not-for-profits to hire